Shield Therapeutics Share Discussion Threads

[rhatton] 30/9/2023 10:36

Times article in photos here

[bagpuss67] 30/9/2023 10:19

Is one able to post the text of the Times article..Im sure the Nestle angle has been discussed here..but good to see the Times mentioning it....

[little minx] 30/9/2023 09:58

How did Nestle acquire their 30% with AOP holding so much? Wonder if they will increase their holding with the new issue.

[r9505571] 30/9/2023 09:19

Tempus has a write up in yesterdays Times pg 42. Nestle has a 30% stake. Tipped as a speculative BUY as the odds are turning in Shields favour.

[cyberbub] 29/9/2023 23:04

Correct bolitix. Always assuming that they achieve their targets! Without wanting to state the bleedin' obvious, that's the bet here... I think we should know by Q2 whether it's working or not... but 80% quarter-on-quarter growth is not to be sniffed at...

GLA

[bolitix] 29/9/2023 21:32

STX cash-burn ($42m) is higher than they make. That should be no surprise to an investor as they have been saying that nearly 2 years that would be the case until YE24. However, YE25 they will make triple of what they cash-burn ($120m).

[eeza] 29/9/2023 20:07

"The front-sellers will have sold from 12p IMO."


Yes, exactly. The placing will have been agreed at least a week before. So 30%+ discount. Easy money for the placees.

[cyberbub] 29/9/2023 19:34

The front-sellers will have sold from 12p IMO.Anyway it's done now, let's see what happens looking forward. Hopefully over the next 12 months they'll be ramping up rapidly and regaining the original revenue trajectory.

[jimbren] 29/9/2023 17:06

The run up late last week/early this week was genuinely innocent excitement ahead of the results. The sell off the day before maybe less innocent but not huge bucks made given the still small volumes on Wednesday in terms of value traded, just £700k, and so someone/people might have made a total of £50-100k - that's not much for the risk of criminal charges -assuming all sold short at average 10 and bought back at average 8. The cops can see who borrowed ST a few days ago to sell a few days later. Hardly any stock lenders in ultra-small cap stocks in AIM with limited free floats.

It will take a while to clear, but it will clear. AOP and new lenders want returns and wouldn't be betting on failure. Viatris have been helpful but I don't see why we can't use their middle office to help with the form filling...?

[eeza] 29/9/2023 16:44

Well Co had a vested interest in getting the share price down on Wed - else the discount on the raise would have been a whole lot higher.

[cyberbub] 29/9/2023 16:32

greyarea, even if someone doesn't *directly* inside trade, as you say it doesn't take a genius if you're approached to be asked if you want some inside information, what that information is. It's not only funds (who you hope are honest) that are approached, many brokers have books of PIs/HNWs who are looking for opportunities to invest (say £100k minimum) and don't want to buy in the market due to illiquidity. Again many of those people will draw their own conclusions and could easily place a quick short spreadbet for £50k virtually anonymously. As soon as a few go in, other market participants realise what's going on (including algos on the technicals) and you get an avalanche effect, stops being triggered, panic, it's a self fulfilling prophecy and the first few to go short make nice money.

[greyarea1] 29/9/2023 16:24

Do you seriously believe any fund would risk going inside not knowing what risk they were taking? This is how it has been communicated to me albeit I haven't sat on a call.

[skcots48] 29/9/2023 16:19

If I'm understanding correctly bestYou doubt the early debt for a team next year or do you mean the team itselfI would argue it's value for money. Keep salesforce out selling rather than the admin of working with prescribers who are already writing scrips but writing too many under the giveaway schemes, and not the fully reimbursed schemes50% or 100% increase of the average price is of huge importance especially if they take off on prescriptions. They have stiff targets now on revenueThey are still missing United Health, Centene Corp and Humana. 3 big insurers not listing accrufer

[tripletop1] 29/9/2023 15:53

"In order to build a book the broker has to approach holders/ potential new holders and ask them if they want to be made inside on some information regarding company X."

Incorrect!

the company is not revealed at all to any degree.. otherwise wouldn't take much to workout what's coming.

[greyarea1] 29/9/2023 15:33

I don't often post on these types of boards but think that I should share some of my knowledge on how these things work and why there can be a sell off pre a raise WITHOUT insider trading.

In order to build a book the broker has to approach holders/ potential new holders and ask them if they want to be made inside on some information regarding company X. The fund then has the option to say yes or no. Given that the (suspected) raise is close to an update many would say no due to being restricted on dealing and in addition raising money at the minute is terrible and so many will be saying no due to liquidity, hence a risk that the fundraise might get drawn out and the fund is stuck as an insider.

The flip side of this is that they now know that SOMETHING is going on regarding company X, they also then bet that a raise is coming, will be at a discount and that there's a quick turn to be made. Hence your sell off and not one person has insider traded.

[best1467] 29/9/2023 15:10

The main problem is why the loan I can understand paying off AOP to get the IP under control .
Does anyone buy fortification of the balance The team of 11/13 they say been Employed to improve Pricing not expected until next year to be up and running .I’ve seen no genuine reason to take on that debt

[cyberbub] 29/9/2023 14:20

Of course it's not hard. But it's not done. How else do City spivs make their money?

[dexdringle] 29/9/2023 12:50

Sorry, I should have said "until someone is held accountable" for what happened on Wednesday. I was implying that 'getting to the bottom of it' would then need to lead to that...

[cyberbub] 29/9/2023 12:25

Dex we know exactly why it is FGS, how long have you been in the markets? The broker tapped some investors for the placing, told them it was strictly confidential, they said they would buy 2 million shares, promised to keep it confidential then went out and shorted 2 million shares and dropped 'heavy hints' to their mates to do the same. Nice £100k profit in 48 hours, bobs your uncle. If you don't understand that that's how it works, you're naive. We can complain to the FCA (and I have) but there will be no consequences.The real question is whether the company management were part of the insider trading? If they were then clearly it would be a bargepole company. But there's no evidence of that and personally I think they're perfectly honest in that regard (competence/effectiveness is a different question of course).No advice intended etc

[dexdringle] 29/9/2023 12:15

Until we get to the bottom of why the share price fell 30% on Wednesday, STX remains toxic.

[skcots48] 29/9/2023 12:08

Show me a business that doesn't need up front investmentShow me a drug development and launch that doesn't need up front investmentAs a 1 product company and not well known they are a higher risk investment But as with all drugs, it catches on and it's a cash bonanza, it doesn't then goodbye Shield. If you're invested and don't understand these risks you're stupidThat said, they did say they had enough money until end of 2024 so more than disappointed they messaged that and raided for more money again now

[someuwin] 29/9/2023 10:35

Edison...

Valuation:

£390.4m or 50p per share Our valuation is largely unchanged at £390.4m from £388.9m previously. The slight adjustment reflects revisions to our short-term estimates reflecting H123 results and tweaked near-term management guidance, and an updated net cash balance. Our per share valuation decreases to 50p (66p previously) given the higher share count.

[zeus19] 29/9/2023 10:22

Edison note just came outShield Therapeutics' H123 results were largely as expected. Despite the minor operational adjustments with the commercialisation ramp-up, our long-term expectations remain unchanged. H123 revenue of $4.3m grew 65.8% y-o-y and was largely driven by US Accrufer sales. Total prescriptions grew 59% (vs H222) to 26,200 and are anticipated to accelerate in H223 with the completed build out of its sales platform. For the medium term, we anticipate additional launches in the EU and regulatory approvals in China and our longer-term assumptions remain unchanged. Our valuation remains largely unchanged at £390.4m (£388.9m previously), reflecting updates to net cash (including the recent $6.1m equity raise) and our near-term estimate adjustments for volume and operating expenses in line with latest management guidance.

[hamidahamida] 29/9/2023 09:30

The company has been burning more money than it makes, and it has been on financial life support ever since listing.Chart tells a story Think about it